Search This Blog

Sunday, May 22, 2016

Amgen Data To Be Presented At ASCO 2016 Demonstrates More Insights Into Treatment Options For Patients

New Analysis From Phase 3 Trial of Kyprolis® (Carfilzomib) Combination Treatment in Relapsed Multiple Myeloma Patients With Early Disease Progression
Phase 1/3 MASTERKEY-265 Study Abstracts Present Data on IMLYGIC® (Talimogene Laherparepvec) in Combination With Pembrolizumab in Patients With Unresected Stage IIIB-IV Melanoma


Amgen - Investors - RSS Content
Posted by at
Labels:

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)